IE 11 is a very old Browser and it`s not supported on this site
de en
Annual Report 2023
de en
Business reportPerformance/Multi-year comparison
Business Report Performance

Performance/Multi-year comparison

Indexed performance since launch

BB Biotech AG (SIX)-CHF


Annual performance

31.12.2023

SHARE

NAV

NBI TR

2023

(18.1%)

(7.4%)

(4.8%)

2022

(24.3%)

(11.0%)

(9.1%)

2021

8.3%

(11.5%)

3.0%

2020

19.3%

24.3%

15.8%

2019

18.5%

23.4%

23.0%

Cumulated performance

31.12.2023

SHARE

NAV

NBI TR

1 year

(18.1%)

(7.4%)

(4.8%)

3 years

(32.9%)

(27.0%)

(10.9%)

5 years

(5.0%)

11.9%

27.0%

10 years

149%

96%

84%

since inception 1)

1 880%

1 860%

1 196%

1 09.11.1993

Annualized performance

31.12.2023

SHARE

NAV

NBI TR

1 year

(18.1%)

(7.4%)

(4.8%)

3 years

(12.4%)

(10.0%)

(3.8%)

5 years

(1.0%)

2.3%

4.9%

10 years

9.5%

6.9%

6.3%

since inception 1)

10.4%

10.4%

8.9%

1 09.11.1993

BB BIOTECH AG (XETRA)-EUR


Annual performance

31.12.2023

SHARE

NAV

NBI TR

2023

(15.2%)

(1.3%)

1.3%

2022

(19.0%)

(6.7%)

(4.5%)

2021

13.3%

(7.8%)

7.4%

2020

18.1%

24.8%

16.1%

2019

23.4%

28.1%

27.6%

Cumulated performance

31.12.2023

SHARE

NAV

NBI TR

1 year

(15.2%)

(1.3%)

1.3%

3 years

(22.2%)

(15.1%)

3.9%

5 years

13.4%

35.7%

53.9%

10 years

223%

159%

143%

since inception 1)

1 724%

1 731%

1 367%

1 10.12.1997

Annualized performance

31.12.2023

SHARE

NAV

NBI TR

1 year

(15.2%)

(1.3%)

1.3%

3 years

(8.0%)

(5.3%)

1.3%

5 years

2.5%

6.3%

9.0%

10 years

12.4%

10.0%

9.3%

since inception 1)

11.8%

11.8%

10.8%

1 10.12.1997

Multi-year comparison

2023

2022

2021

2020

2019

Market capitalization at the end of the period (in CHF mn)

2 368.4

3 058.1

4 274.1

4 107.9

3 670.3

highchart-toggle

Net Asset Value at the end of the period (in CHF mn)

2 323.2

2 686.1

3 283.5

3 887.5

3 393.0

highchart-toggle

Number of shares (in mn)

55.4

55.4

55.4

55.4

55.4

highchart-toggle

Trading volume (in CHF mn)

906.3

1 482.0

2 101.0

2 315.6

2 004.2

highchart-toggle

Profit/(loss) (in CHF mn)

(206.6)

(357.8)

(404.8)

691.2

677.4

highchart-toggle

Closing price at the end of the period in CHF

42.75

55.20

77.15

74.15

66.25

highchart-toggle

Closing price at the end of the period in EUR

45.50

56.70

74.05

68.00

61.40

highchart-toggle

Stock performance (incl. distributions) 1)

(18.1%)

(24.3%)

8.3%

19.3%

18.5%

highchart-toggle

High/low share price in CHF

60.70/35.60

78.15/51.00

92.20/73.40

74.70/45.44

73.20/59.35

highchart-toggle

High/low share price in EUR

60.50/37.10

75.40/49.60

86.20/67.80

69.00/43.04

64.70/52.10

highchart-toggle

Premium/(discount) (annual average)

7.5%

20.5%

19.5%

9.2%

11.8%

highchart-toggle

Dividend in CHF (*proposal)

2.00*

2.85

3.85

3.60

3.40

highchart-toggle

Degree of investment (quarterly figures)

113.7%

112.8%

108.6%

106.8%

109.1%

highchart-toggle

Total Expense Ratio (TER) p.a. 2)

1.34%

1.27%

1.22%

1.25%

1.26%

highchart-toggle

1All figures in CHF %, total return-methodology

2Based on market capitalization

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience. Use of cookies & disclaimer
Accept cookies